ImmuneBridge
PrivateLast Round
Seed
Mar 23, 2026
Total Funding Raised
$19.7M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
ImmuneBridge operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Seed round in March 2026.
ImmuneBridge is a biotechnology company developing allogeneic cellular immunotherapies that enhance the body's healing capabilities by expanding cord blood-derived immune stem cells to create a reliable and versatile source for cancer treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmuneBridge Comparables
Compare ImmuneBridge with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ONK Therapeutics | 68% | |
| NK:IO | 66% | |
| Garuda Therapeutics | 63% |
For institutional investors. Book with your work email.
ImmuneBridge Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Mar 23, 2026 | ||||
| Seed | Apr 10, 2023 |
For institutional investors. Book with your work email.
ImmuneBridge Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LongGame Ventures | Seed |
| NFX | Seed |
| One Way Ventures | Seed |
| Gaingels | Seed |
| M Ventures | Seed |
| T.Rx Capital | Seed |
| Healthspan Capital | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 59% MoM, reaching 2K.
- Jul 29, 2026
Grew 19% QoQ, from 16 to 19 employees.
For institutional investors. Book with your work email.
ImmuneBridge Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImmuneBridge's valuation, stock price, and market status.
Is ImmuneBridge a public or private company?
ImmuneBridge is a private company.
What is the current stock price of ImmuneBridge?
ImmuneBridge is a private company, so its shares have no public market price. Caplight tracks ImmuneBridge's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmuneBridge worth (valuation)?
Valuation information for ImmuneBridge is not publicly available.
Can I buy ImmuneBridge stock?
ImmuneBridge shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmuneBridge's last funding round?
ImmuneBridge's most recent funding round was Seed on March 23, 2026.
Who are the main investors in ImmuneBridge?
Key investors in ImmuneBridge include NFX, M Ventures, Insight Partners.
Will ImmuneBridge IPO soon?
No public IPO plans have been announced for ImmuneBridge.
How can I track ImmuneBridge secondary market activity?
Caplight tracks bids, offers, and trades in ImmuneBridge's shares on secondary markets.